Compass Therapeutics (CMPX) Expected to Announce Earnings on Monday

Key Points

• Compass Therapeutics is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.13) per share.
• The company's stock recently traded down 1.9%, closing at $2.90, with a market capitalization of $400.32 million.
• Analyst ratings for Compass Therapeutics are largely positive, with a consensus rating of "Buy" and a price target averaging $12.67 per share.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Trading Down 1.9%

CMPX stock traded down $0.06 during trading on Monday, hitting $2.90. The company had a trading volume of 175,618 shares, compared to its average volume of 1,383,204. The firm has a market capitalization of $400.32 million, a price-to-earnings ratio of -7.06 and a beta of 1.49. The business has a 50 day moving average of $2.64 and a 200 day moving average of $2.48. Compass Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $4.08.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on CMPX shares. Raymond James Financial upgraded shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a research report on Tuesday, July 1st. D. Boral Capital restated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Monday, April 28th. Guggenheim cut their price objective on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, HC Wainwright restated a "buy" rating and set a $24.00 price objective on shares of Compass Therapeutics in a report on Monday, April 21st. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $12.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Compass Therapeutics stock. Strs Ohio bought a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 17,900 shares of the company's stock, valued at approximately $34,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.